Cargando…

Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials

BACKGROUND: Saffron (stigma of Crocus sativus L.) from Iridaceae family is a well-known traditional herbal medicine that has been used for hundreds of years to treat several diseases such as depressive mood, cancer and cardiovascular disorders. Recently, anti-dementia property of saffron has been in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayati, Zahra, Yang, Guoyan, Ayati, Mohammad Hossein, Emami, Seyed Ahmad, Chang, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650148/
https://www.ncbi.nlm.nih.gov/pubmed/33167948
http://dx.doi.org/10.1186/s12906-020-03102-3
_version_ 1783607458390867968
author Ayati, Zahra
Yang, Guoyan
Ayati, Mohammad Hossein
Emami, Seyed Ahmad
Chang, Dennis
author_facet Ayati, Zahra
Yang, Guoyan
Ayati, Mohammad Hossein
Emami, Seyed Ahmad
Chang, Dennis
author_sort Ayati, Zahra
collection PubMed
description BACKGROUND: Saffron (stigma of Crocus sativus L.) from Iridaceae family is a well-known traditional herbal medicine that has been used for hundreds of years to treat several diseases such as depressive mood, cancer and cardiovascular disorders. Recently, anti-dementia property of saffron has been indicated. However, the effects of saffron for the management of dementia remain controversial. The aim of the present study is to explore the effectiveness and safety of saffron in treating mild cognitive impairment and dementia. METHODS: An electronic database search of some major English and Chinese databases was conducted until 31st May 2019 to identify relevant randomised clinical trials (RCT). The primary outcome was cognitive function and the secondary outcomes included daily living function, global clinical assessment, quality of life (QoL), psychiatric assessment and safety. Rev-Man 5.3 software was applied to perform the meta-analyses. RESULTS: A total of four RCTs were included in this review. The analysis revealed that saffron significantly improves cognitive function measured by the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinical Dementia Rating Scale-Sums of Boxes (CDR-SB), compared to placebo groups. In addition, there was no significant difference between saffron and conventional medicine, as measured by cognitive scales such as ADAS-cog and CDR-SB. Saffron improved daily living function, but the changes were not statistically significant. No serious adverse events were reported in the included studies. CONCLUSIONS: Saffron may have the potential to improve cognitive function and activities of daily living in patients with Alzheimer’s disease and mild cognitive impairment (MCI). However, due to limited high-quality studies there is insufficient evidence to make any recommendations for clinical use. Further clinical trials on larger sample sizes are warranted to shed more light on its efficacy and safety.
format Online
Article
Text
id pubmed-7650148
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76501482020-11-09 Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials Ayati, Zahra Yang, Guoyan Ayati, Mohammad Hossein Emami, Seyed Ahmad Chang, Dennis BMC Complement Med Ther Research Article BACKGROUND: Saffron (stigma of Crocus sativus L.) from Iridaceae family is a well-known traditional herbal medicine that has been used for hundreds of years to treat several diseases such as depressive mood, cancer and cardiovascular disorders. Recently, anti-dementia property of saffron has been indicated. However, the effects of saffron for the management of dementia remain controversial. The aim of the present study is to explore the effectiveness and safety of saffron in treating mild cognitive impairment and dementia. METHODS: An electronic database search of some major English and Chinese databases was conducted until 31st May 2019 to identify relevant randomised clinical trials (RCT). The primary outcome was cognitive function and the secondary outcomes included daily living function, global clinical assessment, quality of life (QoL), psychiatric assessment and safety. Rev-Man 5.3 software was applied to perform the meta-analyses. RESULTS: A total of four RCTs were included in this review. The analysis revealed that saffron significantly improves cognitive function measured by the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinical Dementia Rating Scale-Sums of Boxes (CDR-SB), compared to placebo groups. In addition, there was no significant difference between saffron and conventional medicine, as measured by cognitive scales such as ADAS-cog and CDR-SB. Saffron improved daily living function, but the changes were not statistically significant. No serious adverse events were reported in the included studies. CONCLUSIONS: Saffron may have the potential to improve cognitive function and activities of daily living in patients with Alzheimer’s disease and mild cognitive impairment (MCI). However, due to limited high-quality studies there is insufficient evidence to make any recommendations for clinical use. Further clinical trials on larger sample sizes are warranted to shed more light on its efficacy and safety. BioMed Central 2020-11-09 /pmc/articles/PMC7650148/ /pubmed/33167948 http://dx.doi.org/10.1186/s12906-020-03102-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Ayati, Zahra
Yang, Guoyan
Ayati, Mohammad Hossein
Emami, Seyed Ahmad
Chang, Dennis
Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials
title Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials
title_full Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials
title_fullStr Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials
title_full_unstemmed Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials
title_short Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials
title_sort saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650148/
https://www.ncbi.nlm.nih.gov/pubmed/33167948
http://dx.doi.org/10.1186/s12906-020-03102-3
work_keys_str_mv AT ayatizahra saffronformildcognitiveimpairmentanddementiaasystematicreviewandmetaanalysisofrandomisedclinicaltrials
AT yangguoyan saffronformildcognitiveimpairmentanddementiaasystematicreviewandmetaanalysisofrandomisedclinicaltrials
AT ayatimohammadhossein saffronformildcognitiveimpairmentanddementiaasystematicreviewandmetaanalysisofrandomisedclinicaltrials
AT emamiseyedahmad saffronformildcognitiveimpairmentanddementiaasystematicreviewandmetaanalysisofrandomisedclinicaltrials
AT changdennis saffronformildcognitiveimpairmentanddementiaasystematicreviewandmetaanalysisofrandomisedclinicaltrials